New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”…
Bravo Flowdex: How This Innovative Platform is Redefining AI Trading Read Bravo Flowdex Spain Report!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction –…
Net Rowdex: Why Net Rowdex 2025 Emerges as a Next-Gen AI Trading Platform for Investors Read France Report!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction to…
Immediate Edge: Exploring the AI Technology Behind Immediate Edge Trading Platform Germany Insights!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction to…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma…
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
September 19, 2025 16:18 ET | Source: MBX Biosciences, Inc. CARMEL, Ind.,…
CEA Industries Board Authorizes $250 Million Stock Buyback Program
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq:…
RedCloud to Present AI-Native Vision to Digitize and Transform Global Trade
LONDON, Sept. 19, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT)…
